| (9-81)<br>10 CFR 35  | APPLICATION FOR MATERIALS LICENSE - MEDICAL   |  |   |   |   |  | App<br>315<br>Exp   | 0-0041<br>ires 9-30-83                        |
|--|---|--|---|---|---|--|---|---|
| INSTRUCTIONS - c<br>where nec<br>applicatio<br>20555. U<br>ance with<br>Code of F<br>license fee                               | Complete Items 1 th<br>ressary. Item 26 mu<br>in to : Director, Ofi<br>Ion approval of thi<br>the general require<br>rederal Regulations,<br>a category should be | nough 26 if t<br>at be comple<br>fice of Nucle<br>s application<br>ments contai<br>Parts 19, 20<br>t stated in Ite | this & an initial appli<br>teted on all applicatio<br>ar Materials Safety a<br>, the applicant will r<br>ned in Title 10, Codi<br>and 35 and the licer<br>tm 26 and the appro | cation or an application for re<br>ins and signed. Retain one co<br>ind Safeguards, U.S. Nuclear F<br>eceive a Materials License. Ai<br>e of Federal Regulations, Part<br>se fee provision of Title 10, C<br>priate fee enclosed. | nnewal of a license. L<br>by: Submit original a<br>legulatory Commissio<br>n NRC Materials Lice<br>30, and the Licensee<br>ode of Federal Regul | lse suppli<br>ind one c<br>on, Washi<br>nse is issu<br>is subjec<br>lations, P | emental s<br>opy of ei<br>ngton, D<br>ued in aci<br>it to Title<br>art 170. | theets<br>ntire<br>.C.<br>cord-<br>to,<br>The |
| 1.a. NAME AND MAILING<br>firm, clinic, physician, e<br>War Memorial F<br>500 Osborn Bou<br>Sault Ste, Mar<br>TELEPHONE NO.: AB | ADDRESSOF<br>etc./INCLUDE 2<br>Hospital<br>ilevard<br>tie, Michig   | gan 497  | T linsutution,<br>WAUB<br>283<br>3331   | 1.5. STREET ADDRE<br>WILL BE USED (/  | SS(ES) AT WHICH<br>f different from 1.  | ARADI  | OACTIV  | VE MATERIAL<br>ZIP CODE                       |
| 2. PERSON TO CONTACT   | REGARDING T   | HIS APPLI  | CATION  | 3. THIS IS AN APPLI   | CATION FOR:   |  |   |   |
| James E. Carey   | , M.S.  |  |   |   |   |  |   |   |
| TELEPHONE NC. ARE  | A CODE ( 313)   | 7 64   | 2129  | New License   |   |  |   |   |
| <ol> <li>INDIVIDUAL USERS (A<br/>supervise use of radioactin<br/>for each individual.)</li> <li>See Item 8 on pa</li> </ol>    | Vame individuals<br>ve material. Comp<br>ge 5.  | who will<br>plete Suppl  | use or directly<br>ements A and B   | 5. RADIATION SAFET<br>as radiation safety offic<br>me of training and expe<br>Robert B. Bal   | Y OFFICER (RSC<br>er. If other than indi<br>vience as in Suppleme<br>ker. M.D.  | 0) (Nam<br>ividual us<br>ent A.)   | e of per<br>er, comp  | rson designated<br>lete resu-                 |
|  |   |  |   |   |   |  |   |   |
| S.a. RADIOACTIVE MA  | ATERIAL FOR   | MEDICA   | L USE   | 1   |   |  |   |   |
| RADIOACTIVE MAT  | ERIAL   | ITEMS<br>DESIRED   | MAXIMUM<br>POSSESSION<br>LIMITS<br>(In millicuties)   | ADDITION  | AL ITEMS:   | MA<br>ITE<br>DESI  | RK<br>MS<br>RED   | MAXIMUM<br>POSSESSION<br>LIMITS               |
| O CFR 31.11 FOR IN VITE  | ROSTUDIES   | N/A  |   | IODINE-131 AS IODIO   | DE FOR TREATM   | ENT  | N/A   |   |
| 0 CFR 35,100, SCHEDULE   | A, GROUP I  | X  | AS NEEDED   | PHOSPHORUS 32 AS SOLUBLE PHOSPHATE  |   | N/A  |   |   |
| 0 CFR 35.100, SCHEDULE   | A, GROUP II   | X  | ASNEEDED  | PHOSPHORUS 32 AS  | ND BONE METAS   | TASES  | N/A   |   |
| 0 CFR 35.100, SCHEDULE   | A, GROUP III  | X  | 2000  | MENT OF MALIGNAN  | T EFFUSIONS.  | REA I-   |   |   |
| 0 CFR 35.100,SCHEDULE  | A, GROUP IV   | N/A  | ASNEEDED  | CAVITARY TREATM<br>EFFUSIONS.   | ENT OF MALIGN   | ANT  | N/A   |   |
| 0 CFR 35.100, SCHEDULE   | A, GROUP V  | N/A  | AS NEEDED   | OF THYROID CARCIN   | NOMA  | ENT  | NA  |   |
| D CFR 25.100, SCHEDULE   | A. GROUP VI   | N/A  |   | BLOOD FLOW STUDI<br>FUNCTION STUDIES  | ES AND PULMON   | IARY   | N/A   |   |
| i.b RADIOACTIVE Ma<br>calibration and referen  | ATERIAL FOF   | authorized   | OT LISTED IN<br>under Section 35  | ITEM 6.a. (Sealed source<br>14(d), 10 CFR Part 35, a  | s up to 3 mCi used fo<br>nd NEED NOT BE   | T<br>LISTE   | D.)   |   |
| ELEMENT AND MAS  | S NUMBER  | PHY  | MEMICAL<br>AND/OR<br>SICAL FORM   | MAXIMUM NUMBER<br>OF MILLICURIES<br>OF EACH FORM  | DESCRIB   | E PURI   | POSE O  | F USE   |
|  |   |  |   | Applican  | Sept-1  | 141  | TL  | -1  |
|  | Li  | cense Fee  | : Information<br>9 /13/8 L &<br>and Skie  | Check N<br>Amount/<br>Type of P<br>Liste Che<br>Received  | b. 125.76 K<br>Fee Calegory<br>ee Appli<br>ck Rep'd.9/2<br>By/2005  | * 19<br>tal  |   | Ret   |
| RC FORM 313M   | FEE   |  | PT,70.  | 11 w)19)+   | 89040404<br>REG3 LIC<br>21-20318  | 90 E<br>30<br>-01  | 8040  | D7<br>PNU                                     |

.

|   | IN MATION REQUIRED  | FOR                                   | TI'EMS 7 THROUGH 23   |
|---|---|---------------------------------------|---|
| For<br>eact<br>you<br>num<br>*NO<br>Rev | Items 7 through 23, check the appropriate box(es) and subminister on a separate sheet. Identify the item number and the indicate that an appendix to the medical licensing guide will uber and date of the referenced guide: Regulatory Guide 10.1 TE: All appendices referenced on this patision 1, and are attached to the applicat | date d<br>be fol<br>B<br>ge a<br>ion. | letailed description of all the requested information. Begin<br>of the application in the lower right corner of each page. If<br>llowed, do not submit the pages, but specify the revision<br>,*Rev Date:<br>re based on Regulatory Guide 10.8,<br>Some appendices have been slightly |
| mod                                     | ified to reduce the regulatory burden.  | 15                                    | GENERAL RULES FOR THE SAFE USE OF   |
| 7. n<br>X                               | Names and Specialties Attached; and (See Page 5)  |                                       | RADIOACTIVE MATERIAL <i>(Check One)</i> (Page 16)<br>Appendix G Rules Followed; or  |
| x                                       | Duties as in Appendix B; or   | X                                     | Equivalent Rules Attached   |
|   | Equivalent Duties Attached  | 16.                                   | EMERGENCY PROCEDURES (Check One) (Page 17)  |
| 8. 7                                    | RAINING AND EXPERIENCE (Page 5)   |                                       | Appendix H Procedures Followed; or  |
| X                                       | Supplements A & B Attached for Each Individual User;  |                                       | Equivalent Procedures Attached  |
|   | Supplement A Attached for RSO.  | 17.                                   | AREA SURVEY PROCEDURES (Check One) (Page 18)  |
| 9. 1                                    | NSTRUMENTATION (Check One) (Page 6)   | X                                     | Appendix   Procedures Followed; or  |
| X                                       | Appendix C Form Attached; or  |                                       | Equivalent Procedures Attached  |
|   | List by Name and Model Number   | 18.                                   | WASTE DISPOSAL (Check One) (Page 19)  |
| 10.                                     | CALIBRATION OF INSTRUMENTS (Page 7)   | X                                     | Appendix J Form Attached; or  |
| X                                       | Appendix D. Procedures Followed for Survey  |                                       | Equivalent Information Attached   |
|   | Equivalent Procedures Attached; and   | 19.                                   | THERAPEUTIC USE OF RADIOPHARMACEUTICALS<br>(Check One)  |
| X                                       | Appendix D Procedures Followed for Dose<br>Calibrator; or   | N/A                                   | Appendix K Procedures Followed; or  |
|   | Equivalent Procedures Attached  |                                       | Equivalent Procedures Attached  |
| 11.                                     | FACILITIES AND EQUIPMENT (Page 12)  | 20.                                   | THERAPEUTIC USE OF SEALED SOURCES   |
| x                                       | Description and Diagram Attached  | N/A                                   | Detailed Information Attached; and  |
| 12.                                     | PERSONNEL TRAINING PROGRAM (Page 13)  |                                       | Appendix L Procedures Followed; or (Check One)  |
| X                                       | Description of Training Attached  |                                       | Equivalent Procedures Attached  |
| 13.                                     | PROCEDURES FOR ORDERING AND RECEIVING<br>RADIOACTIVE MATERIAL (Page 14)   | 21.                                   | PROCEDURES AND PRECAUTIONS FOR USE OF<br>RADIOACTIVE GASES (e.g., Xenon – 133)  |
| X                                       | Detailed Information Attached   | N/A                                   | Detailed Information Attached   |
| 14.                                     | PROCEDURES FOR SAFELY OPENING PACKAGES<br>CONTAINING RADIOACTIVE MATERIALS  | 22.                                   | PROCEDURES AND PRECAUTIONS FOR USE OF<br>RADIOACTIVE MATERIAL IN ANIMALS  |
|   | (Page 15)   | N/A                                   | PROCEDURES AND PRECAUTIONS FOR USE OF   |
| X                                       | Appendix F Procedures Followed; or  | 23.                                   | RADIOACTIVE MATERIAL SPECIFIED IN ITEM 6.0  |
|   | Equivalent Procedures Attached  | N/A                                   | Detailed Information Attached   |

NRC FORM 313M (9-81)

Page 2

| the second se |  |   | 24. PERSONNEL MONIT  | ORING DEVICES  |   |
|---|--|---|--|--|---|
| (Che  | TYP<br>ck approp   | E<br>priate box)  | SUPPLIER   |  | EXCHANGE FREQUENCY  |
|   | X F  | ILM   | Siemens  |  | monthly   |
| a. WHOLE<br>BODY  | т  | LD  |  |  |   |
|   | 0  | THER (Specify)  |  |  |   |
|   | F  | I L M   |  |  |   |
| b. FINGER   | х т  | LD  | Siemens  | 1999 (d. 1999) - Harris I. (d. 1997) - Harri | monthly   |
|   | 0  | THER (Specify)  |  |  |   |
|   | F  | ILM   |  |  |   |
| c. WRIST  | т  | LD  |  |  |   |
|   | 0  | THER (Specify)  |  | -  |   |
| d. OTHER  | (Specity)  | ALARA PROGRAM   | М  |  |   |
|   |  |   |  |  |   |
|   |  |   | •  |  |   |
|   |  | 25. 1   | FOR PRIVATE PRACTICE APP   | LICANTS ONLY   |   |
| a NOSPITA   | AL AGRE  | 25. I<br>EING TO ACCEPT P   | FOR PRIVATE PRACTICE APP<br>ATIENTS CONTAINING RADIOAC   | LICANTS ONLY   |   |
| a NOSPITA<br>NAME O   | AL AGRE  | 25. I<br>EING TO ACCEPT P<br>FAL  | FOR PRIVATE PRACTICE APP<br>ATIENTS CONTAINING RADIOAC<br>N.A.   | LICANTS ONLY<br>TIVE MATERIAL<br>b. ATTACH A COP<br>SIGNED BY THE  | Y OF THE AGREEMENT LETTER<br>HOSPITAL ADMINISTRATOR.  |
| a HOSPITA<br>NAME O<br>MAILING  | AL AGRE  | 25. I<br>EING TO ACCEPT P<br>TAL<br>SS  | FOR PRIVATE PRACTICE APP<br>ATIENTS CONTAINING RADIOAC<br>N.A.   | LICANTS ONLY<br>TIVE MATERIAL<br>b. ATTACH A COP<br>SIGNED BY THE<br>c. WHEN REQUEST<br>ATTACH A COPY  | Y OF THE AGREEMENT LETTER<br>HOSPITAL ADMINISTRATOR.  |
| a HOSPITA<br>NAME O<br>MAILING<br>CITY  | AL AGRE  | 25. I<br>EING TO ACCEPT P<br>TAL<br>SS  | FOR PRIVATE PRACTICE APP<br>ATIENTS CONTAINING RADIOAC<br>N.A.   | C. WHEN REQUEST<br>ATTACH A COPY<br>SIGNED BY THE<br>C. WHEN REQUEST<br>ATTACH A COPY<br>TIONS TO BE TA<br>RADIATION DET   | Y OF THE AGREEMENT LETTER<br>HOSPITAL ADMINISTRATOR.<br>TING THERAPY PROCEDURES,<br>Y OF RADIATION SAFETY PRECAU-<br>IKEN AND LIST AVAILABLE<br>FECTION INSTRUMENTS.  |
| a HOSPITA<br>NAME O<br>MAILING<br>CITY  | AL AGRE<br>DF HOSPI<br>G ADDRE   | 25. I<br>EING TO ACCEPT P<br>TAL<br>SS  | FOR PRIVATE PRACTICE APP<br>ATIENTS CONTAINING RADIOAC<br>N.A.<br>STATE ZIP CO<br>26. CERTIFICAT<br>(This item must be completed   | CLICANTS ON LY<br>CTIVE MATERIAL<br>b. ATTACH A COP<br>SIGNED BY THE<br>c. WHEN REQUEST<br>ATTACH A COPY<br>TIONS TO BE TA<br>RADIATION DET<br>TE<br>( by applicant)   | Y OF THE AGREEMENT LETTER<br>HOSPITAL ADMINISTRATOR.<br>TING THERAPY PROCEDURES,<br>Y OF RADIATION SAFETY PRECAU-<br>IKEN AND LIST AVAILABLE<br>FECTION INSTRUMENTS.  |
| a HOSPITA<br>NAME O<br>MAILING<br>CITY<br>The applic<br>conformation of the second                              | AL AGRE<br>DF HOSPI<br>G ADDRE   | 25. I<br>EING TO ACCEPT P<br>TAL<br>SS<br>any official executing<br>the 10, Code of Fede<br>true and correct to the   | FOR PRIVATE PRACTICE APP<br>ATIENTS CONTAINING RADIOAC<br>N.A.<br>STATE ZIP CO<br>26. CERTIFICAT<br>(This item must be completed<br>this certificate on behalf of the app<br>ral Regulations, Parts 30 and 35, and<br>e best of our knowledge and belief.                                      | CLICANTS ON LY<br>TIVE MATERIAL<br>b. ATTACH A COP<br>SIGNED BY THE<br>c. WHEN REQUEST<br>ATTACH A COPY<br>TIONS TO BE TA<br>RADIATION DET<br>TE<br>(by applicant)<br>dicant named in Item 1a cert<br>d that all information contain   | Y OF THE AGREEMENT LETTER<br>HOSPITAL ADMINISTRATOR.<br>TING THERAPY PROCEDURES,<br>Y OF RADIATION SAFETY PRECAU-<br>KEN AND LIST AVAILABLE<br>TECTION INSTRUMENTS.   |
| a HOSPITA<br>NAME O<br>MAILING<br>CITY<br>The applic<br>conformat<br>attached P                                 | AL AGRE<br>DF HOSPI<br>G ADDRE   | 25. I<br>EING TO ACCEPT P<br>TAL<br>SS<br>any official executing<br>the 10. Code of Fede<br>true and correct to the<br>a LICENSE FE<br>(See Section 170.)           | FOR PRIVATE PRACTICE APP<br>ATIENTS CONTAINING RADIOAC<br>N.A.<br>STATE ZIP CO<br>26. CERTIFICAT<br>(This item must be completed<br>this certificate on behalf of the app<br>ral Regulations, Parts 30 and 35, and<br>best of our knowledge and belief.<br>E REQUIRED<br>31, 10 CFR 170)       | LICANTS ON LY<br>TIVE MATERIAL<br>b. ATTACH A COP<br>SIGNED BY THE<br>c. WHEN REQUEST<br>ATTACH A COPY<br>TIONS TO BE TA<br>RADIATION DET<br>TE<br>( by applicant)<br>Dicant named in Item 1a cert<br>that all information contain<br>b. APPLICANT OR C<br>L) NAME (Type   | Y OF THE AGREEMENT LETTER<br>HOSPITAL ADMINISTRATOR.<br>TING THERAPY PROCEDURES,<br>Y OF RADIATION SAFETY PRECAU-<br>KEN AND LIST AVAILABLE<br>TECTION INSTRUMENTS.   |
| a HOSPITA<br>NAME O<br>MAILING<br>CITY<br>The appli-<br>conformit<br>attached P                                 | AL AGRE<br>DF HOSPI<br>G ADDRE<br>cant and<br>ty with Th<br>hereto, is t | 25. I<br>EING TO ACCEPT P<br>TAL<br>SS<br>any official executing<br>the 10, Code of Fede<br>true and correct to the<br># LICENSE FE<br>(See Section 170,<br>ATEGORY | FOR PRIVATE PRACTICE APP<br>ATIENTS CONTAINING RADIOAC<br>N.A.<br>STATE ZIP CO<br>26. CERTIFICAT<br>(This item must be completed<br>this certificate on behalf of the app<br>ral Regulations, Parts 30 and 35, and<br>best of our knowledge and belief.<br>E REQUIRED<br>31, 10 CFR 120)<br>7B | DUE<br>C. WHEN REQUEST<br>ATTACH A COP<br>SIGNED BY THE<br>C. WHEN REQUEST<br>ATTACH A COP<br>TIONS TO BE TA<br>RADIATION DET<br>TE<br>(by applicant)<br>Dicant named in Item 1a cert<br>that all information contain<br>D. APPLUGANT OB C<br>H) NAME (Type<br>Robert T<br>(2) TITLE<br>C MALE MODO  | Y OF THE AGREEMENT LETTER<br>HOSPITAL ADMINISTRATOR.<br>TING THERAPY PROCEDURES,<br>Y OF RADIATION SAFETY PRECAU-<br>KEN AND LIST AVAILABLE<br>TECTION INSTRUMENTS.<br>UNITY that this application is prepared in<br>ned herein, including any supplements<br>CERTIFYING OFFICIAL (Signature)<br>WID<br>MD<br>SI PILING<br>SI PILING AKER M.D.<br>DOT. OF RADIOLOTY |

| - 61 |   |   |  |  |
|------|---|---|--|--|
|      | · |   |  |  |
|      |   |   |  |  |
|      |   | - |  |  |
|      |   |   |  |  |

1.0.0.M 31.3M (9.0.1)

# PRIVACY ACT STATEMENT

Pursuant to 5 U.S.C. 552a(e)(3), enacted into law by section 3 of the Privacy Act of 1974 (Public Law 93-579), the following statement is furnished to individuals who supply information to the Nuclear Regulatory Commission on NRC Form 313M. This information is maintained in a system of records designated as NRC-3 and described at 40 Federal Register 45334 (October 1, 1975).

- 1. AUTHORITY Sections 81 and 161(b) of the Atomic Energy Act of 1954, as amended (42 U.S.C. 2111 and 2201(b)).
- PRINCIPAL PURPOSE(S) The information is evaluated by the NRC staff pursuant to the criteria set forth in 10 CFR Parts 30-36 to determine whether the application meets the requirements of the Atomic Energy Act of 1954, as amended, and the Commission's regulations, for the issuance of a radioactive material license or amendment thereof.
- 3. ROUTINE USES The information may be used: (a) to provide records to State health departments for their information and use; and (b) to provide information to Federal, State, and local health officials and other persons in the event of incident or exposure, for their information, investigation, and protection of the public health and safety. The information may also be disclosed to appropriate Federal, State, and local agencies in the event that the information indicates a violation or potential violation of law and in the course of an administrative or judicial proceeding. In addition, this information may be transferred to an appropriate Federal, State, or local agency to the extent relevant and necessary for a NRC decision or to an appropriate Federal agency to the extent relevant and necessary for that agency's decision about you. A copy of the license issued will routinely be placed in the NRC's Public Document Room, 1717 H Street, N.W., Washington, D.C.
- 4. WHETHER DISCLOSURE IS MANDATORY OR VOLUNTARY AND EFFECT ON INDIVIDUAL OF NOT PROVIDING INFORMATION Disclosure of the requested information is voluntary. If the requested information is not furnished, however, the application for radioactive material license, or amendment thereof, will not be processed.
- 5. SYSTEM MANAGER(S) AND ADDRESS Director, Division of Fuel Cycle and Material Safety, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555.

NRC FORM 313M (9-81)

| OHM NRC                  | 313M-SUPPLEMENT A  |  | U.S. NUCL                                    | EAR REGUL                   | ATORY COMMISSION  |  |  |
|--------------------------|--|--|--|-----------------------------|---|--|--|
| (-78)                    | AUTHORIZ   | TRAINING AND EXPERIMED USER OR RADIATION SA    | ENCE<br>FETY OFFICER                         |                             |   |  |  |
| . NAME OF                | AUTHORIZED USER OR R   | ADIATION SAFETY OFFICER                        |  | 2. STATE OR                 | TERRITORY IN  |  |  |
| ROBER                    | T B. BAKER, M.D.   |  |  | PRACTICE                    | MEDICINE  |  |  |
|                          |  | 3. CEPTIFICATION                               |  |                             |   |  |  |
|                          | A  | B  |  | MONTHAND                    | C   |  |  |
| Ameri<br>of Ra           | can Board<br>diology   | Diagnostic Rad                                 | iology                                       | Jun                         | ne 1976   |  |  |
|                          | 4. TRAINING  | RECEIVED IN BASIC RADIOISOTO                   | ED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES |                             |   |  |  |
|                          |  |  |  | TYPE AND LENGTH OF TRAINING |   |  |  |
|                          | FIELD OF TRAINING<br>A   | LOCATION AND DATE (                            | LOCATION AND DATE (2) OF TRAINING<br>B       |                             | / SUPERVISED<br>RY LABORATORY<br>S EXPERIENCE<br>(Hours)<br>D |  |  |
| 8, RAC<br>INS            | DIATION PHYSICS AND<br>TRUMENTATION                              | Mayo Clinic<br>Rochester, MN<br>Jan 1, - April | 55901<br>1, 1975                             | 35                          | 175   |  |  |
| b. RAS                   | DIATION PROTECTION   | As Above                                       |  | 5                           | 25  |  |  |
| C. MA<br>TH<br>OF        | THEMATICS PERTAINING T<br>E USE AND MEASUREMENT<br>RADIOACTIVITY | As Above                                       |  | 5                           | 15  |  |  |
| d. RADIATION BIOLOGY     |  | As Above                                       | As Above                                     |                             |   |  |  |
| e. RA<br>Ch              | DIOPHARMACEUTICAL<br>EMISTRY                                     | As Above                                       |  | 5                           | 25  |  |  |
| 5. EXPERIENCE WITH RADIA |  | WITH RADIATION. (Actual use of F               | ledioisotopes or Eq.                         | uivalent Exper              | ienco)  |  |  |
| ISOTOPE                  | MAXIMUM AMOUNT   | WHERE EXPERIENCE WAS GAINED                    | DURATION OF I                                | XPERIENCE                   | TYPE OF US?   |  |  |
| Mo-99<br>Tc-99m          | 500 millicuries<br>25 millicuries                                | Mayo Clinic<br>Mayo Clinic                     | Jan 1 - Apr<br>Jan 1 - Apr                   | 1, 1975<br>1, 1975          | Generator<br>Compounding/<br>Clinical                         |  |  |
| I-131                    | 100 microcuries  | Mayo Clinic                                    | Jan 1 - Apr                                  | 1, 1975                     | Clinical  |  |  |

Marine 70

A/290

and an ever the second production is the second second and the second second the second second second and and

E

No.

LORIAN RC-313M-SUPPLEMENT B

1

## U. S. NUCLEAR REGULATORY COMMISSION

# PRECUPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

| 1. APPLICA    | NT PHYSICIAN'S NAME AND ADD HESS                   |                                   | KEY TO COLUMN C                              |  |  |
|---------------|--|-----------------------------------|--|--|--|
| Rok           | ert Bruce Baker                                    | MD                                | PE1<br>1-Supervise<br>radiaisot<br>prescribe | RSONAL PARTICIPATION SHOULD CONSIST OF:<br>ed examination of patients to determine the suitability for<br>ope diagnosis and/or treatment and recommendation for<br>d dosage. |  |
| STREET        | OKBORN BIND  |                                   | 2-Collabora<br>to the pa<br>measurer         | ation in dose calibration and actual adstration of do <del>se</del><br>tient including calculation of the rack- son dose, related<br>ments and plotting of data.             |  |
| CITY          | STATE ZIP C  | ODE                               | 3-Adequat                                    | e period of training to enable physician to manage radioactive   |  |
| GALL          | T STE MARIE MT. 44                                 | 0743                              | treatmen                                     | it.  |  |
|               | 2. CLINICAL TRAINING AND                           | EXPERI                            | ENCE OF                                      | ABOVE NAMED PHYSICIAN  |  |
| 15 DTOPE<br>A | CONDITIONS DIAGNOSED OR TREATED                    | NUM<br>CASES IN<br>PERS<br>PARTIC | BER OF<br>IVOLVING<br>ONAL<br>IPATION        | COMMENTS<br>(Additional information or comments may<br>be submitted in duplicate on separate shoets.)<br>D   |  |
|               | DIAGNOSIS OF THYROID FUNCTION                      | 40                                | >  |  |  |
|               | DE TERMINATION OF BLOOD AND<br>BLOOD PLASMA VOLUME | N/A                               |  |  |  |
| 1430          | LIVE & FUNCTION STUDIES                            | NA                                |  |  |  |
| 1 125         | FAT ASSORPTION STUDIES                             | N/f                               | 4  |  |  |
|               | KIONEY FUNCTION STUDIES                            | 2                                 |  |  |  |
|               | IN MITRO STUDIES                                   | N/t                               | 4  |  |  |
| COTHER.       | 11-123 THYROID IMAGING                             | 35                                | 5  |  |  |
| 1 125         | DETECTION OF THROMBOSIS                            | 30                                | >  |  |  |
| 4-134         | THYROID IMAGING                                    | N/A                               | 4  |  |  |
| P-32          | EVE TUMOR LOCALIZATION                             | N/A                               | A  |  |  |
| Sc-75         | PANCREASTRAGING                                    | N/                                | 7  |  |  |
| Yb-169        | CISTERNOGRAPHY                                     | 1                                 |  |  |  |
| Ne-133        | PULMONARY FUNCTION STUDIES                         | 250                               | 2  |  |  |
| OTHER         |  |                                   |  |  |  |
|               | SRADI MAGING                                       | 20                                | 0  |  |  |
|               | CARDIAC MAGING                                     | 60                                |  |  |  |
|               | PIYROID MAGINE                                     | 15                                | 0  |  |  |
|               | SNUTRARY OLAND INAGLIG                             | N/                                | A  |  |  |
| Telen         | ALGOD PODL MAGING                                  | 30                                | >  |  |  |
|               | PLACENTALOCALIZATION                               | N/                                | A  |  |  |
|               |  | 400                               | C  |  |  |
|               | LENG PRACING                                       | 25                                | 0  |  |  |
|               | LIGNE CANONIC                                      | 42                                | 5  |  |  |
|               | TI-201 Cardiac Imagina                             | 4                                 | -0   |  |  |
|               |  |                                   |  |  |  |

and a for all we will be

Pare G

|                        | PRECEPTO  | M STRIEMENT (  | contractor)  |
|------------------------|---|--|--|
|                        | 2. CLINICAL TRAINING AND EXI  | PERIENCE OF ABOV                                       | E NAMED PHYSICIAN (Continued)  |
| ISOTOPE                | CONDITIONS DIAGNOSED OR TREATED   | CASES INVOLVING<br>PERSONAL<br>PASITICIPATION<br>C     | COMMENTS<br>(Additional information or comments may be<br>submitted in duplicate on separate sheets.)<br>D |
| P-32<br>(Soluble)      | TREATMENT OF POLYCYTHEMIA VERA,<br>LEUKEMIA, AND BONE METASTASES  | NGA  |  |
| P-22<br>(Calkridat)    | INTRACA JITARY TREATMENT  | NA   |  |
| 1.4.54                 | TREATMENT OF THYROID CARCINOMA  | NA   |  |
| 1-131                  | TREATMENT OF HYPERTHYROIDISM  | N/A  |  |
| Au-198                 | INTRACAVITARY TREATMENT   | NA   |  |
| Co-60                  | INTERS ITIAL TREATMENT  | NA   |  |
| Gs-137                 | INTRACAVITARY TREATMENT   | NA   |  |
| 1-125<br>or<br>tr-102  | INTERST/TIAL TREATMENT  | N/A  |  |
| Cr:60<br>or<br>Cs-137  | TELETHERAPY TREATMENT   | MA   |  |
| Sr-90                  | TREATMENT OF EYE DISEASE  | N/A  |  |
|                        | RADIOPHARMACEUTICAL PREPARATION   |  |  |
| teto-007<br>Tri-99m    | GENERATOR   | 5  |  |
| 54-113/<br>10-113m     | GENERATOR   | N/A  |  |
| To-98m                 | REAGENT KITS  | 5  |  |
|                        |   |  |  |
| - NOVE<br>- TOT<br>RAD | AND TOTAL NUMBER OF HOURS RECE<br>EMBER 1977 - DEC<br>TAL NUMBER OF HOU<br>NO ISUTOPE TRAINING  | IVED IN CLINICAL<br>EMBER 10<br>125 RECENT<br>15 APRRO | RADIOISOTOPE TRAINING<br>961 DATES OF TRAINING<br>VED IN CLINICAL<br>XIMATELY GOD HOURS                    |
|                        | Adming and experience indicated<br>stained under the supervision of<br>e of supervisor<br>C. HIGGINS, M.D.<br>e of institution<br>MMUNITY HOSPITAL<br>INDISS RESS<br>S WEST ST. | ABOVE S. PRECEPT<br>CULU<br>2. PRECEPT<br>CH21         | stopher C. Higgins Mit<br>stopher C. Higgins, Mit  |
| BAT                    | TLE CREEK, MT 49  | 016 8-3  | 31-82  |

1

(3)

FORM NRC-313M-SUPPLEMENT B

. .

## U. S. NUCLEAR REGULATORY COMMISSION

# PRECEPTOR STATEMENT

| APPLIC      | ANT PHYSICIAN'S NAME AND ADDRESS                     |   | KEY TO COLUMN C  |  |  |  |
|-------------|--|---|--|--|--|--|
| FULLN       | AME<br>rt Bruce Baker, M.D.                          | 1-Super<br>radioi<br>prescr                                   | PERSONAL PARTICIPATION SHOULD CONSIST OF:<br>1-Supervised examination of patients to determine the suitability for<br>radioisotope diagnosis and/or treatment and recommendation for |  |  |  |
| STREET      | ADDRESS  | 2-Collab<br>to the  | oration in dose calibration and actual administration of dose<br>patient including calculation of the radiation dose, related<br>rements and plotting of data.                       |  |  |  |
| SUU<br>CITY | USDORN BOULEVARD                                     | CODE 3-Adea   | late period of training to enable physician to manage radioactiv   |  |  |  |
| Saul        | t Ste. Marie MI                                      | 49733 ( patier<br>treatm                                      | ts and follow patients through diagnosis and/or course of<br>sent,   |  |  |  |
|             | 2. CLINICAL TRAINING AND                             | DEX STRIENCE O  | F ABOVE NAMED PHYSICIAN  |  |  |  |
| ISOTCPE     | CONDITIONS DIAGNOSED OR TREATED<br>B                 | NUMBER OF<br>CASES INVOLVIN<br>PERSONAL<br>PARTICIPATION<br>C | G COMMENTS<br>(Additional information or comments may<br>be submitted in duplicate on separate sheets.)<br>D   |  |  |  |
|             | DIAGNOSIS OF THYROID FUNCTION                        | 125   |  |  |  |  |
|             | DETERMINATION OF BLOOD AND<br>BLOOD PLASMA VOLUME    | 100   |  |  |  |  |
| 1-131       | LIVER FUNCTION STUDIES                               | 0   |  |  |  |  |
| or<br>1-125 | FAT ABSORPTION STUDIES                               | 0   |  |  |  |  |
|             | KIDNEY FUNCTION STUDIES                              | 185   |  |  |  |  |
|             | IN VITRO STUDIES                                     | 0   | •  |  |  |  |
| OTHER       | I-131 Adrenal Imaging                                | 7   |  |  |  |  |
| 1-125       | DETECTION OF THROMBOSIS                              | 12  |  |  |  |  |
| 1-131       | THYROID IMAGING                                      | 75  |  |  |  |  |
| P-32        | EYE TUMOR LOCALIZATION                               | 0   |  |  |  |  |
| Se- 75      | PANCREAS IMAGING                                     | 12  |  |  |  |  |
| Yb-169      | CISTERNOGRAPHY                                       | 11  |  |  |  |  |
| Xe-133      | BLOOD FLOW STUDIES AND<br>PULMONARY FUNCTION STUDIES | 320   |  |  |  |  |
| OTHER       | Tc-99m Residual Urine                                | 19  |  |  |  |  |
|             | BRAIN IMAGING  | 264   |  |  |  |  |
|             | CARDIAC IMAGING                                      | 55  |  |  |  |  |
|             | THYROID IMAGING                                      | 378   |  |  |  |  |
|             | SALIVARY GLAND IMAGING                               | 2   |  |  |  |  |
| Tc-99m      | BLOOD POOL IMAGING                                   | 4   |  |  |  |  |
|             | PLACENTA LOCALIZATION                                | 0   |  |  |  |  |
|             | LIVER AND SPLEEN IMAGING                             | 941   |  |  |  |  |
|             | LUNG IMAGING   | 320   |  |  |  |  |
|             | BONE IMAGING   | 871   |  |  |  |  |
| OTHER       | Ga-67 Abscess/tumor scan                             | 124   |  |  |  |  |

FORM NRC-313M-SUPPLEMENT B (8-78)

Page 6

CONTROL NO. 06859

|                           | 2 CLINICAL TRAINING AND EXE  | PERIENCE OF ABOV  | E NAMED PHYSICIAN (Continued)   |
|---------------------------|--|---|---|
| SOTOPE                    | CONDITIONS DIAGNOSED OR TREATED  | NUMBER OF<br>CASES INVOLVING<br>PERSONAL<br>PARTICIPATION | COMMENTS<br>(Additional information or comments may be<br>submitted in duplicate on separate sheets.) |
| P-32                      | B<br>TREATMENT OF POLYCYTHEMIA VERA,   | C   |   |
| Soluble)                  | LEUKEMIA, AND BONE METASTASES  | 0   |   |
| P-32<br>Colloidall        | INTRACAVITARY TREATMENT  | 0   |   |
| 1.1.31                    | TREATMENT OF THYROID CARCINOM  | 0   |   |
|                           | TREATMENT OF HYPERTHYROIDISM   | 0   | •   |
| Au-198                    | INTRACAVITARY TREATMENT  | 0   |   |
| 0-60                      | INTERSTITIAL TREATMENT   | 0   |   |
| or<br>0s-137              | INTRACAVITARY TREATMENT  | 0   |   |
| I-125<br>or<br>Ir-192     | INTERSTITIAL TREATMENT   | 0   |   |
| Co-60<br>or<br>Cs-137     | TELETHE RAPY TREATMENT   | 0   |   |
| Sr-90                     | TREATMENT OF EYE DISEASE   | 0   |   |
|                           | RADIOPHARMACEUTICAL PREPARATION  |   |   |
| Mo-99/<br>Tc-99m          | GENERATOR  | 5   |   |
| Sn-113/                   | GENERATOR  | 0   |   |
| Tc-99m                    | REAGENT KITS   | 5   |   |
| Other                     | Tc-99m Renal Imaging<br>Tc-99m Meckel's scan   | 99<br>13  |   |
| A THE T<br>WAS O<br>A NAM | RAINING AND EXPERIENCE INDICATED<br>RAINING AND EXPERIENCE INDICATED<br>BTAINED UNDER THE SUPERVISION OF<br>ME OF SUPERVISOR<br>MAYO Clinic<br>LINGADDRESS<br>DO So 18 St. | ABOVE C. PRECEP   | TOR'S SIGNATURE<br>tor'S NAME (Please type or print)<br>MANUEL BROWN MD                               |
| 12 UT 13                  | Rochester No 55901   |   | 0/2/02  |

## NAME OF AUTHORIZED USER\*

Robert B. Baker, M.D. (see attached Supplements A & B) AUTHORIZATION

All

## MEMBERS RADIATION SAFETY COMMITTEE

Robert B. Baker, M.D. Chairman - Radiologist Rassul S. Saber , M.D. - Pathologist Kristi Guimond, ARRT, NMTCB - Nuclear Medicine Technologist Jean Gordon, R.N.

Bernard Koenig, III,

Nuclear Medicine Specialist Chief of Pathology - Nurse Director of Nursing - Administrator

\*If you wish to add additional names to the list, follow the instructions in Item 8 on page 4 of Regulatory Guide 10.8.

> Item 8 Page 5

# APPENDIX C

# INSTRUMENTATION

| 1. | Surv                 | vey meters   |               |                        |                  |                    |       |
|----|----------------------|--|---------------|------------------------|------------------|--------------------|-------|
|    | a.                   | Manufacturer's name:   | Eberlinc      |                        |                  |                    |       |
|    |                      | Manufacturer's model number :                                      | E-120         | with HP-1              | 190 thin end-win | dow probe          |       |
|    |                      | Number of instruments available                                    | :             |                        |                  |                    |       |
|    |                      | Minimum range:0  | mR/hr to      | .2                     | _ mR/hr          |                    |       |
|    |                      | Maximum range:0  | mR/hr to      | 20                     | mR/hr            |                    |       |
|    | b.                   | Manufacturer's name :  | Eberline      |                        |                  |                    |       |
|    |                      | Manufacturer's model number:                                       | E-520         | with HP-2              | 270 side-window  | energy compensated | probe |
|    |                      | Number of instruments available                                    | :1            |                        |                  |                    |       |
|    |                      | Minimum range :0.  | _ inR/hr to _ | .2                     | mR/hr            |                    |       |
|    |                      | Maximum range :0   | mR/hr to      | 2000                   | mR/hr            |                    |       |
| 2. | Dose<br>Manu<br>Manu | calibrator<br>afacturer's name:Capin<br>afacturer's model number:1 | tec<br>-5     |                        |                  |                    |       |
| 3. | Instru               | ments used for diagnostic procedu                                  | ıres          |                        |                  |                    |       |
|    | Type                 | of Instrument  |               | Manufacturer's<br>Name |                  | Model No.          |       |
|    | Gamm                 | na Camera  | 1             | Fechnicare             |                  | Wide Field         |       |
|    |                      |  |               |                        |                  |                    |       |

4. Other (e.g., liquid scintillation counter, are: monitor, velometer)

Item 9 Page 6 . . . . . . .

# CALIBRATION OF SURVEY INSTRUMENTS

#### Check appropriate items.

X 1.

X

- 1. Survey instruments will be calibrated at least annually and following repair.
- Calibration will be performed at two points on each scale used for radiation protection purposes, i.e., at least up to 1 R/hr.

The two points will be approximately 1/3 and 2/3 of full scale. A survey instrument may be considered properly calibrated when the instrument readings are within  $\pm 10$  percent of the calculated or known values for each point checked. Readings within  $\pm 20$  percent are considered acceptable if a calibration chart, graph, or response factor is prepared, attached to the instrument, and used to interpret readings to within  $\pm 10$  percent. Also, when higher scales are not checked or calibrated, an appropriate precautionary note will be posted on the instrument.

- 3. Survey instruments will be calibrated
  - a. By the manufacturer

## b. At the licensee's facility

| (1)  | Calibration source<br>Radionuclide  |
|------|---|
|      | Manufacturer's name   |
|      | Model no.   |
|      | Activity in millicuries   |
|      | or  |
|      | Exposure rate at a specified distance   |
|      | Accuracy  |
|      | Traceability to primary standard  |
| (2)  | The calibration procedures in Section 1 of Appendix D will be used  |
| (3)  | The step-by-step procedures, including radiation safety procedures, are attached.   |
| By a | consultant or outside firm  |
| (1)  | NameMedical Physics Consultants   |
| (2)  | Location _Suite B 3200 West Liberty, Ann Arbor, MI 48104  |
| (3)  | Procedures and sources  |
|      | X 21-16327-01 have been approved by NRC and are on file in License No.  |
|      | have been approved by an Agreement State: a copy of the Agreement State license, the procedures, and a description of the sources are attached, and the consultant's report will contain the information on |
|      | the attached "Certificate of Instrument Calibration."<br>the consultant's reporting form as attached.   |
|      | are described in the attachment, and the consultant's report will contain the information on  |
|      | the attached "Certificate of Instrument Calibration."   |

Item 10 Page 7

# CALIBRATION OF DOSE CALIBRATOR

A. Sources Used for Linearity Test

(Check as appropriate)

X First elution from new Mo-99/Tc-99m generator

X If generators are not in use, a source of Tc-99m with Other\*(specify) activity equivalent to the maximum activity assayed to clinical situations will be used.

B. Sources Used for Instrument Accuracy and Constancy Tests

| Radionuclide | Suggested<br>Activity (mCi) | Activity (mCi)          | Accuracy                        |
|--------------|-----------------------------|-------------------------|---------------------------------|
| Co-57        | 3-5                         | One millicurie or more  | within + 5%                     |
| Ba-133       | 0.1-0.5                     | 100 microcuries or more | wi <u>chin Ŧ</u> 5%             |
| Cs-137       | 0.1-0.2                     | 100 microcuries or more | within $\pm$ 5%                 |
| Ra-225       | 1-2                         | N/A                     | N/A                             |
| N/A          |                             | N/A                     | N/A                             |
|              |                             |                         | Contractor through the store of |

C.

X The procedures described in Section 2 of Appendix D will be used for calibration of the dose calibrator

10

\*For licensees who are not authorized for Mo-99/Tc-99m generators, activity must be equivalent to the highest activity used.

## APPENDIX D (Continued)

#### Section 2

#### **METHODS FOR CALIBRATION OF DOSE CALIBRATOR\***

All radiopharmaceuticals must be assayed for activity to an accuracy of 10 percent. The most common instrument for accomplishing this is an ionization-type dose calibrator. The instrument must be checked for accurate operation at the time of installation and periodically thereafter.

- A. Test for the following:
  - 1. Instrument constancy (daily)
  - Instrument accuracy (at installation and annually thereafter)
  - Instrument linearity (at installation and quarterly thereafter)
  - 4. Geometrical variation (at installation)
- B. After repair or adjustment of the dose calibrator, repeat all the appropriate tests listed above (dependent upon the nature of the repairs).
- C. Test for Instrument Constancy

Instrument constancy means that there is reproducibility, within a stated acceptable degree of precision, in measuring a constant activity over time. Assay at least one relatively long-lived reference source such as Cs-137, Co-57,\*\* or Ra-226\*\* using a reproducible geometry before each day's use of the instrument. Preferably, at least two reference sources (for example, 3-5 mCi of Co-57 and 100-200  $\mu$ Ci of Cs-137 or 1-2 mg Ra-226 (with appropriate decay corrections) will be alternated each day of use to test the instrument's performance over a range of photon energies and source activities.

- Assay \_ach reference source using the appropriate instrument setting (i.e., Cs-137 setting for Cs-137).
- Measure background level at same instrument setting, or check that automatic background subtraction is operating properly when blanks are inserted in the calibrator.

- Calculate net activity of each source subtracting out background level.
- For each source, plot net activity versus the day of the year on semilog graph paper.
- 5. Log the background levels.
- Indicate the predicted activity of each source based on decay calculations and the ±5 percent limits on the graph.
- Repeat the procedure used for the Cs-137 source for all the commonly used radionuclide settings.
- Variations greater than ±5 percent from the predicted activity indicate the need for instrument repair or adjustment.
- Investigate higher then normal background levels to determine their origin and to eliminate them if possible by decontamination, relocation, etc.
- D. Inspect the instrument on a quarterly basis to ascertain that the measurement chamber liner is in place and that instrument zero is properly set (see manufacturer's instructions).
- E. Test of Instrument Linearity

The linearity of a dose calibrator should be ascertained over the entire range of activities employed. This test will use a vial of Tc-99m whose activity is equivalent to the maximum anticipated activity to be assayed (e.g., the first elution from a new generator).

- Assay the Tc-99m vial in the dose calibrator, and subtract background level to obtain net activity in millicuries.
- Repeat step 1 at time intervals of 6, 24, 30, and 48 hours after the initial assay.
- Using the 30-hour activity measurement as a starting point, calculate the predicted activities at 0, 6, 24, and 48 hours using the following table:

See ANSI N42.13-1978. "Calibrz-'ion and Usage of Dose Calibrator Ionization Chambers for the Assay of Radionuclides'' (American National Standards Institute, Inc., 1430 Broadway, New York, N.Y. 10018).

<sup>\*\*</sup> Co-57 and Ra-226 are not subject to NRC licensing; the respective State agency should be consulted to determine its requirements for possessing this material.

| Assay Time* (hr) | Correction Factor |
|------------------|-------------------|
| 0                | 31.633            |
| 6                | 15.853            |
| 24               | 1.995             |
| 30               | 1                 |
| 48               | 0.126             |

*Example*: If the net activity measured at 30 hours was 15.625 mCi, the calculated activities for 6 and 48 hours would be 15.625 mCi x 15.853 = 247.7 mCi and 15.625 mCi x 0.126 = 1.97 mCi, respectively.

- On semi-log coordinate paper, plot the net measured activity and the calculated activity versus time.
- 5. The activities plotted should be within ±5 percent of the calculated activity if the instrument is linear and functioning properly. Errors greater than ±5 percent indicate the need for repair or adjustment of the instrument.
- 6. It instrument linearity cannot be corrected, it will be necessary in routine assays to use either (a) an aliguot of the eluate that can be accurately measured or (b) the graph constructed in step 4 to relate measured activities to calculated activities.

#### F. Test for Geometrical Variation

There may be significant geometrical variation in activity measured as a function of sample volume or configuration, depending on the volume and size of the ionization chamber used in the dose calibrator. The extent of geometrical varia ion should be ascertained for commonly used radionuclides and appropriate correction factors computed if variations are significant, i.e., greater than  $\pm 2$  percent. (Even though correction factors may be provided by the manufacturer, the accuracy of these should be checked.) When available from the manufacturer, certified data on geometrical variations may be used in lieu of these measurements.

To measure variation with volume of liquid, a 30-cc vial containing 2 mCi of Co-57 or other appropriate radionuclide in a volume of 1 ml will be used.

- Assay vial at the appropriate instrument setting, and subtract background level to obtain net activity.
- Increase the volume of liquid in the vial in steps to 2, 4, 8, 10, 20, and 25 ml by adding the appropriate amount of water or saline. After each addition, gently shake vial to mix contents and assay

as in step 1. (Follow good radiation safety practices to avoid contamination and to minimize radiation exposure.)

 Select one volume as a standard (such as the volume of reference standard used in performing the test for instrument accuracy), and calculate the ratio of measured activities for each volume to the reference volume activity. This represents the volume correction factor (CF).

> Example: If activities of 2.04, 2.02, and 2.00 mCi are measured for 4, 8, and 10 ml volumes and 10 ml is the reference volume selected.

ml Volume CF = 
$$\frac{2.00}{2.04}$$
 = 0.98

- 4. Plot the correction factors against the volume on linear graph paper. Use this graph to select the proper volume correction factors for routine assay of that radionuclide.
- The true activity of a sample is calculated as follows:

True Activity = Measured Activity x Correction Factor

where the correction factor used is for the same \* volume and geometrical configuration as the sample measured.

- Similarly, the same activity of Co-57 in a syringe may be compared with that of 10 ml in a 30-cc vial, and a correction factor may be calculated.
- 7. It should be noted that differences of 200 percent in dose calibrator readings between glass and plastic syringes have been observed for lowerenergy radionuclides such as 1-125, which should be assayed in a dose calibrator only if the reliability of such an assay can be established. Glass tubes and syringes may also vary enough in thickness to cause significant errors in assaying 1-125. Hence, adequate correction factors must be established.

An alternative to providing syringe calibration factors is to simply assay the stock vial before and after filling the syringe. The activity in the syringe is then the difference in the two readings (with a volume correction if significant).

G. Test for Instrument Accuracy

Check the accuracy of the dose calibrator for several radionuclides, including Cs-137, Co-57, and Ba-133, using appropriate reference standards whose activities have been calibrated by comparisons with standard sources that have been assayed by NBS and documented.

Assay times should be measured in whole hours and correction factors should be used to the third decimal place as indicated. The more recent half-life of T = 6.02 hours has been used in calculating these correction factors. 1/2

The activity levels of the reference sources used should approximate those levels normally encountered in clinical use (e.g., Co-57, 3-5 millicuries) giving adequate attention to source configuration. Identify in your application the three sources that you will use. State nuclide, activity, and calibration accuracy. The lo energy reference standards (Tc-99m, Xe-133, Imust be in vials with the same thickness of glass as actual samples to be measured for best accuracy.

- Assay the reference standard in the dose calibrator at the appropriate setting, and subtract the background level to obtain the net activity.
- Repeat step 1 for a total of 3 determinations, and average results.
- The average activity determined in step 2 should agree with the certified activity of the reference source within ±5 percent after decay corrections.

- Repeat the above steps for other commonly used radionuclides for which adequate reference standards are available.
- 5. Keep a log of these calibration checks.
- 6. Calibration checks that do not agree within ±5 percent indicate that the instrument should be repaired or adjusted. If this is not possible, a calibration factor should be calculated for use during routine assays of radionuclides.
- 7. At the same time the instrument is being initially calibrated at the licensee's facility with the reference standards, place a long-lived source in the calibrator, set the instrument, in turn, at the various radionuclide settings used (Cs-137, I-131, Tc-99m, I-125, etc.), and record the readings. These values may later be used to check instrument calibration at each setting (after correcting for decay of the long-lived source) without requiring more reference standards. Keep a log of these initial and subsequent readings.

War Memorial Hospital 500 Osborn Boulevard Sault Ste. Marie, Michigan 48783

1. Radiopharmaceutical Receipt and Unpackaging

- 2. Hand Sink
- 3. "Dose" Preparation and Compounding Area. Lead Glass Face Shield + lead side shielding (minimum 1/8" thick)
- 4. Mo-99/Tc99m Generator Storage Area + Radioactive Waste Storage. Lead Generator Shield (inherent shielding + manufacturer supplied additional shielding) + lead bricks (minimum 2" thick).
- 5. Undercounter waste storage including used generator storage. Shielded -lead bricks.



Page 12

# PERSONNEL TRAINING PROGRAM

I. Individuals who work in or inequent restricted areas will be instructed in the items specified in 10 CFR 19.12 at the time of initial employment and at least annually thereafter.

This instruction will include:

- a. All terms of the license pertinent to radiation safety.
- b. Areas where radioactive material is used or stored.
- c. Potential hazards associated with radioactive material.
- d. Radiological safety procedures appropriate to their respective duties.
- e. Pertinent NRC regulations.
- f. Rules and regulations of the license.
- g. Obligation to report unsafe conditions to the radiation safety officer.
- h. Appropriate response to emergencies or unsafe conditions.
- i. Right to be informed of their radiation exposure and bioassay results.
- j. Locations where the licensee has posted or made available notices, copies of pertinent regulations, and copies of pertinent licenses and license conditions (including applications and applicable correspondence), as required by 10 CFR Part 19.
- II. Individuals whose duties may require them to work in the vicinity of licensed material will be informed about radiation hazards and appropriate precautions at the time of initial employment and at least annually thereafter. This information will be provided initially at hospital employee orientation sessions and annually thereafter at in-service meetings.

Item 12 Page 13

CONTROL NO. 06859

## APPENLIX E

#### PROCEDURES FOR ORDERING AND ACCEPTING DELIVERY OF RADIOACTIVE MATERIAL

- The Supervisory Nuclear Medicine Technologist will place all orders for radioactive materials and will ensure that the requested materials and quantities are authorized by the ficense and that possession limits are not exceeded.
- A system for ordering and receiving radioactive materials will be established and maintained. The system will consist minimally of the following.
  - a. Ordering of routinely used materials
    - Written records that identify the isotope, compound, activity levels, and supplier, etc., will be used.
    - (2) The written records will be referenced when opening or storing radioactive shipment.
  - b. Ordering of specially used materials (e.g., theras peutic uses)

- A written request\* will be obtained from the physician who will perform the procedure.
- (2) Persons ordering the materials will reference the physician's written request when placing the order. The physician's request will indicate isotope, compound, activity level, etc.
- (3) The physician's written request will be referenced when receiving, opening, or storing the radioactive material.
- It is essential that written records<sup>e</sup> be maintained for all ordering and receipt procedures.
- During normal working hours, carriers will be instructed to deliver radioactive packages directly to the Nuclear Medicine Department.
- 4. During off-duty hours, security personnel or other designated individuals will accept delivery of radioactive packages in accordance with the procedures outlined in the sample memorandum below.

## SAMPLE\*\* MEMORANDUM

MEMORANDUM FOR: Security Personnel

FROM: Hospital Administrator

SUBJECT: RECEIPT OF PACKAGES CONTAINING RADIOACTIVE MATERIAL

Any packages containing radioactive material that arrive between 4:30 p.m. and 7 a.m. or on Sundays shall be signed for by the Security Guard on duty and taken immediately to the Nuclear Medicine Department. Unlock the door, place the package on top of the counter immediately to the right of the door, and relock the door.

If the package is wet or appears to be damaged immediately contact the Radiation Safety Officer. Ask the carrier to remain until it can be dtermined that neither he nor the delivery vehicle is contaminated.

----

\*\*RADIATION SAFETY OFFICER

\*\*OFFICE PHONE

\*\*HOME PHONE

\*\*On the actual memo that is used, this information will be filled in and updated as necessary.

> Item 13 Page 14

CONTROL NO. 06859

In the case of special orders, the physician's written request and appropriate shipping/receipt records will be referenced and the dose assayed prior to its administration.

## APPENDIX F

## PROCEDURES FOR SAFELY OPENING PACKAGES CONTAINING RADIOACTIVE MATERIAL

- 1 Special requirements will be followed for packages containing quantities of radioactive material in excess of the Type A quantity limits as specified in paragraphs 20.205(a)(1) and (c)(1) of 10 CFR Part 20 (more than 20 Ci for Mo-99 and Tc-99m). They will be monitored for surface contamination and external radiation levels within 3 hours after receipt if received during working hours or within 18 hours if received after working hours, in accordance with the requirements of paragraphs 20.205(a) through (c). All shipments of liquids greater than exempt quantities will be tested for leakage. The NRC Regional Office will be notified in accordance with the regulations if removable contamination exceeds 0.01  $\mu$ Ci/100 cm<sup>2</sup> or if external radiation levels exceed 200 mR/hr at the package surface or 10 mR/hr at 3 feet (or 1 m).
- For all packages, the following additional procedures for opening packages will be carried out:
  - a. Put on gloves to prevent hand contamination.
  - Visually inspect package for any sign of damage (e.g., wetness, crushed). If damage is noted, stop procedure and notify Radiation Safety Officer.
  - c. Measure exposure rate at 3 feet (or 1 m) from package surface and record. If >10 mR/hr, stop procedure and notify Radiation Safety Officer.
  - Measure surface exposure rate and record. If >200 mR/hr, stop procedure and notify Radiation Safety Officer.
  - Open the package with the following precautionary steps.
    - Open the outer package (following manufacturer's directions, if supplied) and remove packing slip.

- (2) Open inner package and verify that contents agree with those on packing slip. Compare requisition,\* packing slip, and label on bottle.
- (3) Check integrity of final source container (i.e., inspect for breakage of seals or vials, loss of liquid, and discoloration of packaging material).
- (4) Check also that shipment does not exceed possession limits.
- f. Wipe external surface of final source container shield and remove wipe to low background area. Check wipes with a thinend-window G-M survey meter, and take precaution against the spread of contamination as necessary.
- Monitor the packing material and packages for contamination before discarding.
  - (1) If contaminated, treat as radioactive waste.
  - (2) If not contaminated, obliterate radiation labels before discarding in regular trash.
- Maintain records of the results of checking each package, using "Radioactive Shipment Receipt Record" (see next page) or a form containing the same information.

Item 14 Page 15

In the case of special orders (e.g., therapy doses), also compare with physician's written request.

## APPENDIX G

#### GENERAL RULES FOR SAFE USE OF RADIOACTIVE MATERIAL

- Wear laboratory coats or other protective clothing at all times in areas where radioactive materials are used.
- Wear disposable gloves at all times while handling radioactive materials.
- Monitor hands and clothing for contamination after each procedure or before leaving the area.
- 4. Always use syringe shields for routine preparation of patient doses and administration to patients, except in circumstances such as pediatric cases when their use would compromise the patient's well-being. In these exceptional cases, use other protective methods such as remote delivery of the dose (e.g., through use of a butterfly valve).
- a. Do not eat, drink, smoke, or apply cosmetics in any area where radioactive material is stored or used.
  - b. Do not store food, drink, or personal effects with radioactive material.
- a. Assay each patient dose in the dose calibrator prior to administration. Do not use any doses that differ from the prescribed dose by more than 10 percent.
  - b. For therapeutic doses, also check the patient's name, the radionuclide, the chemical form, and the activ-

ity vs. the order written by the physician who will perform the procedure.

- 7. Wear personnel monitoring devices (film badge or TLD) at all times while in areas where radioactive materials are used or stored. These devices should be worn at chest or waist level. Personnel monitoring devices when not being worn to monitor occupational exposures should be stored in a designated low background area.
- Wear TLD finger badges during elution of generator and preparation, assay, and injection of radiopharmaceuticals.
- Dispose of radioactive waste only in specially designated and properly shielded receptacles.
- 10. Never pipette by mouth.
- Survey generator, kit preparation, and injection areas for contamination after each procedure or at the end of the day. Decontaminate if necessary.
- Confine radioactive solutions in covered containers plainly identified and labeled with name of compound, radionuclide, date, activity, and radiation level, if applicable.
- Always transport radioactive r. sterial in shielded containers.

Item 15 Page 16

CONTROL NO. 06859

#### APPENDIX H

#### EMERGENCY PROCEDURES

#### Minor Spills

- NOTIFY: Notify persons in the area that a spill has occurred.
- PREVENT THE SPREAD : Cover the spill with absorbent paper.
- 3. CLEAN UP: Use disposable gloves and remote handling tongs. Carefully fold the absorbent paper and pad. Insert into a plastic bag and dispose of in the radioactive waste container. Also insert into the plastic bag all other contaminated materials, such as disposable gloves.
- SURVEY: With a low-range, thin-window G-M survey meter, check the area around the spill, hands, and clothing for contamination.
- REPORT: Report incident to the Radiation Safety Officer.

#### Major Spills

- CLEAR THE AREA: Notify all persons not involved in the spill to vacate the room.
- PREVENT THE SPREAD: Cover the spill with absorbent pads, but do not attempt to clean it up. Confine the movement of all personnel potentially contaminated to prevent the spread.

- SHIELD THE SOURCE: If possible, the spill should be shielded, but only if it can be done without further contamination or without significantly increasing your radiation exposure.
- CLOSE THE ROOM: Leave the room and lock the door(s) to prevent entry.
- CALL FOR HELP: Notify the Radiation Safety Officer immediately.
- PERSONNEL DECONTAMINATION: Contaminated clothing should be removed and stored for further evaluation by the Radiation Safety Officer. If the spill is on the skin, flush thoroughly and then wash with mild soap and lukewarm water.

\*RADIATION SAFETY OFFICER : \_\_\_\_\_\_ \*OFFICE PHONE : \_\_\_\_\_\_ \*HOME PHONE : \_\_\_\_\_\_

\*ALTERNATE NAMES AND TELEPHONE NUMBERS DESIGNATED BY RADIATION SAFETY OFFICER

\*On the actual copy that is posted in the nuclear medicine department, this information will be filled in and updated as necessary.

## APPENDIX I

#### AREA SURVEY PROCEDURES

- All elution, preparation, and injection areas will be surveyed daily with an appropriately low-range survey meter and decontaminated if necessary.\*
- 2. Laboratory areas where only small quantities of radioactive material are used (less than 200  $\mu$ Ci) will be surveyed monthly.
- Waste storage areas and all other laboratory areas will be surveyed weekly.
- 4. The weekly and monthly surveys will consist of :
  - a. A measurement of radiation levels with a survey meter sufficiently sensitive to detect 0.1 mR/hr.
  - b. A series of wipe tests to measure contamination levels. The method for performing wipe tests will be sufficiently sensitive to detect 200 dpm per 100 cm<sup>2</sup> for the contaminant involved. Wipes of elution and preparation areas or other "high background" areas will be removed to a low background area for measurement.

- A permanent record will be kept of all survey results, including negative results. The record will include:
  - Location, date, and identification of equipment used, including the serial number and pertinent counting efficiencies.
  - b. Name of person conducting the survey.
  - Drawing of area surveyed, identifying relevant features such as active storage areas, active waste areas, etc.
  - Measured exposure rates, keyed to location on the drawing (point out rates that require corrective action).
  - Detected contamination levels, keyed to locations on drawing.
  - f. Corrective action taken in the case of contamination or excessive exposure rates, reduced contamination levels or exposure rates after corrective action, and any appropriate comments.

6.

Area will be cleaned if the contamination level exceeds 200 dpm/100 cm<sup>2</sup>.

For daily surveys where no abnormal exposures are found, only the date, the identification of the person performing the survey, and the survey results will be recorded.

## APPENDIX J

#### WASTE DISPOSAL

Note : In view of the recent problems with shallow-land burial sites used by commercial waste disposal firms, NRC is encouraging its licensees to reduce the volume of wastes sent to these facilities. Important steps in volume reduction are to segregate radioactive from nonradioactive waste, to hold short-lived radioactive waste for decay in storage, and to release certain materials in the sanitary sewer in accordance with § 20.303 of 10 CFR Part 20.

1. Liquid waste will be disposed of (check as appropriate)

X In the sanitary sewer system in accordance with § 20.303 of 10 CFR Part 20. -0r-

- N/A By commercial waste disposal service (see also Item 4 below).
- Other (specify): See #3 X
- 2. Mo-99/Tc-99m generators will be (check as appropriate)

X Returned to the manufacturer for disposal. -or-

X Held for decay\* until radiation levels, as measured in a low background area with a low-level survey meter and with all shielding removed, have reached background levels. All radiation labels will be removed or obliterated, and the generators will be disposed of as normal trash.\*\*

N/A Disposed of by commercial waste disposal service (see also Item 4 below).

N/A Other (specify):

- 3. Other solid waste will be (check as appropriate)
  - X Held for decay\* until radiation levels, as measured in a low background area with a low-leve! survey meter and with all shielding removed, have reached background levels. All radiation labels will be removed or obliterated, and the waste will be disposed of in normal trash.
  - N/A Disposed of by commercial waste disposal service (see also Item 4 below).
  - N/A Other (specify):
  - The commercial waste disposal service used will be 4.

(City, State)

NRC/Agreement State License No. N/A

Item 18 Page 19

N/A (Name)

Be sure that waste storage areas were described in Item 11 and that they are surveyed periodically (Item 17).

<sup>\*\*</sup> These generators may contain long-lived radioisotopic contaminants. Therefore, the generator columns will be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

#### APPENDIX O

# AT MEDICAL INSTITUTIONS ALARA

War Memorial Hospital

(Licensee's Name)

#### 8/16/82

(Date)

#### Management Commitment

- a. We, the management of this (medical facility, hospital, etc.), are committed to the program described in this paper for keeping exposures (individual and collective) as low as is reasonably achievable (ALARA). In accord with this commitment, we hereby describe an administrative organization for radiation safety and will develop the necessary written policy, procedures, and instructions to foster the ALARA concept within our institution. The organization will include a Radiation Safety Committee (RSC)<sup>1</sup> and a Radiation Safety Officer (RSO).
- b. We will perform a formal annual review of the radiation safety program, including ALARA considerations. This shall include reviews of operating procedures and past exposure records, inspections, etc., and consultations with the radiation protection staff or outside consultants.
- c. Modification to operating and maintenance procedures and to equipment and facilities will be made where they will reduce exposures unless the cost, in our judgment, is considered to be unjustified. We will be able to demonstrate, if necessary, that improvements have been sought, that modifications have been considered, and that they have been implemented where reasonable. Where modifications have been recommended but not implemented, we will be prepared to describe the reasons for not implementing them.
- d. In addition to maintaining doses to individuals as far below the limits as is reasonably achievable, the sum of the doses received by all exposed individuals will also be maintained at the lowest practicable level. It would not be desirable, for example, to hold the highest doses to individuals to some fraction of the applicable limit if this involved exposing additional people and significantly increasing the sum of radiation doses received by all involved individuals.

#### 2. Radiation Safety Committee (RSC)<sup>2</sup>

- a. Review of Proposed Users and Uses
  - (1) The RSC will thoroughly review the qualifications of each applicant with respect to the types and quantities of materials and uses for which he has applied to ensure that the applicant will be able to take appropriate measures to maintain exposure ALARA.
  - (2) When considering a new use of byproduct material, the RSC will review the efforts of the applicant to maintain exposure ALARA. The user should have systematized procedures to ensure ALARA and shall have incorporated the use of special equipment such as syringe shields, rubber gloves, etc., in his proposed use.
  - (3) The RSC will ensure that the user justifies his procedures and that dose will be ALARA (individual and collective).
- h. Delegation of Authority

(The judicious delegation of RSC authority is essential to the enforcement of an ALARA program.)

- The RSC will delegate authority to the RSO for enforcement of the ALARA concept.
- (2) The RSC will support the RSO in those instances where it is necessary for the RSO to assert his/her authority. Where the RSO has been overruled, the Committee will record the basis for its action in the minutes of the Committee's quarterly meeting.

<sup>&</sup>lt;sup>1</sup>Private practice physician licenses do not include an RSC.

 $<sup>^{2}</sup>$ The RSO on private practice physician licenses will assume the responsibilities of the RSC under Section 2.

c. Rev

- Review of ALARA Program
- The RSC will encourage all users to review current procedures and develop new procedures as appropriate to implement the ALARA concept.
- (2) The RSC will perform a quarterly review of occupational radiation exposure with particular attention to instances where Investigational Levels in Table 0-1 below are exceeded. The principal purpose of this review is to assess trends in occupational exposure as an index of the ALARA program quality and to decide if action is warranted when Investigational Levels are exceeded (see Section 6).<sup>3</sup>
- (3) The RSC will evaluate our institution's overall efforts for maintaining exposures ALARA on an annual basis. This review will include the efforts of the RSO, authorized users, and workers as well as those of management.

#### 3. Radiation Safety Officer (RSO)

- a. Annual and Quarterly Review
  - Annual review of the radiation safety program. The RSO will perform an annual review of the radiation safety program for adherence to ALARA concepts. Reviews of specific procedures may be conducted on a more frequent basis.
  - (2) Quarterly review of occupational exposures. The RSO will review at least quarterly the external radiation exposures of authorized users and workers to determine that their exposures are Ai.ARA in accordance with the provisions of Section 6 of this program.
  - (3) Quarterly review of records of radiation level surveys. The RSO will review radiation levels in unrestricted and restricted areas to determine that they were at ALARA levels during the previous quarter.
- b. Education Responsibilities for ALARA Program
  - The RSO will schedule briefings and educational sessions to inform workers of ALARA program efforts.

- (2) The RSO will ensure that authorized users, workers, and ancillary personnel who may be exposed to radiation will be instructed in the ALARA philosophy and informed that management, the RSC, and the RSO are committed to implementing the ALARA concept.
- c. Cooperative Efforts for Development of ALARA Procedures

Radiation workers will be given opportunities to participate in formulation of the procedures that they will be required to follow.

- The RSO will be in close contact with all users and workers in order to develop ALARA procedures for working with radioactive materials.
- (2) The RSO will establish procedures for receiving and evaluating the suggestions of individual workers for improving health physics practices and will encourage the use of those procedures.
- d. Reviewing Instances of Deviation from Good ALARA Practices

The RSO will investigate all known instances of deviation from good ALARA practices and, if possible, will determine the causes. When the cause is known, the RSO will require changes in the program to maintain exposures ALARA.

#### 4. Authorized Users

- New Procedures Involving Potential Radiation Exposures
  - (1) The authorized user will consult with, and receive the approval of, the RSO and/or RSC during the planning stage before using radioactive materials for a new procedure.
  - (2) The authorized user will evaluate all procedures before using radioactive materials to ensure that exposures will be kept ALARA. This may be enhanced through the application of trial runs.
- Responsibility of Authorized User to Persons Under His/Her Supervision
  - The authorized user will explain the ALARA concept and his/her commitment to maintain exposures ALARA to all persons under his/her supervision.
  - (2) The authorized user will ensure that persons under his/her supervision who are

Item 24 Cont'd Page 21

<sup>&</sup>lt;sup>3</sup>The NRC has emphasized that the Investigational Levels in this program are not new dose limits but, as noted in ICRP Report 26, "Recommendations of the International Commission on Radiological Protection." serve as check points above which the results are considered sufficiently important to justify further investigations.

subject to occupational radiation exposure are trained and educated in good health physics practices and in maintaining exposures ALARA.

#### 5. Persons Who Receive Occupational Radiation Exposure

- a. The worker will be instructed in the ALARA concept and its relationship to working procedures and work conditions.
- b. The worker will know what recourses are available if he/she feels that ALARA is not being promoted on the job.
- Ectablishment of Investigational Levels In Order to Monitor Individual Occupational External Radiation Exposures

This institution (or private practice) hereby establishes Investigational Levels for occupational external radiation exposure which, when exceeded, will initiate review or investigation by the RSC and/or the RSO. The Investigational Levels that we have adopted arc listed in Table O-1 below. These levels apply to the exposure of individual workers.

#### Table 0-1

#### Investigational Levels (mrems per calendar quarter)

|    |  | Level 1 | Level II |  |
|----|--|---------|----------|--|
| 1. | Whole body; head and<br>trunk ; active blood-forming<br>organs; lens of eyes; or<br>gonads | 125     | 375      |  |
| 2. | Hands and forearms; feet<br>and ankles   | 1875    | 5625     |  |
| 3. | Skin of whole body*  | 750     | 2250     |  |

Not normally applicable to nuclear medicine operations except those using signifi ant quantities of beta-emitting isotopes.

The Radiation Safety Officer will review and record on Form NRC-5, "Current Occupational External Radiation Exposures," or an equivalent form (e.g., dosimeter processor's report), results of personnel monitoring not less than once in any calendar quarter as required by § 20.401 of 10 CFR Part 20. The following actions will be taken at the Investigational Levels as stated in Table 0-1: Quarterly exposure of individuals to less than Investigational Level I.

a.

Except when deemed appropriate by the RSO, no further action will be taken in those cases where an individual's exposure is less than Table 0-1 values for the Investigational Level I.

 Personnel exposures equal to or greater than Investigational Level I, but less than Investigational Level II.

> The RSO will review the exposure of each individual whose quarterly exposures equal or exceed Investigational Level I and will report the results of the reviews at the first RSC meeting following the quarter when the exposure was recorded. If the exposure does not equal or exceed Investigational Level II, no action related specifically to t! e exposure is required unless deemed appropriate by the Committee. The Committee will, however, consider each such exposure in comparison with those of others performing similar tasks as an index of ALARA program quality and will record the review in the Committee minutes.

c. Exposure equal to or greater than Investigational Level II.

The RSO will investigate in a timely manner the cause(s) of all personnel exposures equaling or exceeding Investigational Level II and, if warranted, will take action. A report of the investigation, actions taken, if any, and a copy of the individual's Form NRC-5 or its equivalent will be presented to the RSC at the first RSC meeting following completion of the investigation. The details of these reports will be recorded in the RSC minutes. Committee minutes will be sent to the management of this institution for review. The minutes, containing details of the investigation, will be made available to NRC inspections.

d. Reestablishment of an individual occupational worker's Investigational Level II to a level above that listed in Table 0-1.

> In cases where a worker's or a group of workers' exposures need to exceed Investigational Level II, a new, higher Investigational Level II may be established on the basis that it is consistent with good ALARA practices for that individual or group. Justification for a new Investigational Level II will be documented.

The RSC will review the justification for, and will approve, all revisions of Investigational Level II. In such cases, when the exposure equals or exceeds

> Item 24 Cont'd Page 22

CONTROL NO. 06859

the newly established Investigational Level II, those actions listed in paragraph 6.c above will be followed.

## 7. Signature of Certifying Official<sup>4</sup>

I hereby certify that this institution (or private practice) has implemented the ALARA Program set forth above.

 $^{4}$ The person who is authorized 20 make commitments for the dministration of the institution (e.g., hospital administrator) or, n the case of a private practice, the licensed physician.

Signature MD K Name (print or type) 64 barman ADIO Title

Institution (or Private Practice) Name and Address:

| Wal  | THE | HOL 1 | al no | SPILE | H T.    |       |
|------|-----|-------|-------|-------|---------|-------|
| 500  | Os  | born  | Boul  | evar  | đ       |       |
| Saul | t   | Ste.  | Mari  | e. M  | ichigan | 49783 |